Healthcare provider profile · identity verified

Kenneth K Lee, MD

Allopathic & Osteopathic Physicians|Family Medicine · GLEN ELLYN, IL · NPI 1043245970

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Kenneth K Lee, MD received $98.14 in general payments during 2025 across 2 reported records.

Becton, Dickinson and Company accounted for 64.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$98.14

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Becton, Dickinson and Company Unresolved — no canonical attribution shown $63.4064.6%12025
Corium, LLC Unresolved — no canonical attribution shown $34.7435.4%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$98.142

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
HemoSphere
Normalized: hemosphere
Device Becton, Dickinson and Company $63.40 1 2025
Source payment records
Azstarys
Normalized: azstarys
Drug Corium, LLC $34.74 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Atorvastatin CalciumAtorvastatin Calcium380115
Amlodipine BesylateAmlodipine Besylate25976
Losartan PotassiumLosartan Potassium20759
LisinoprilLisinopril20253
Levothyroxine SodiumLevothyroxine Sodium19658
Metoprolol SuccinateMetoprolol Succinate14843
HydrochlorothiazideHydrochlorothiazide14441
SimvastatinSimvastatin13840
Metformin Hcl ErMetformin Hcl10131
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen9814
AlprazolamAlprazolam9223
GabapentinGabapentin9220
Pantoprazole SodiumPantoprazole Sodium9028
Tamsulosin HclTamsulosin Hcl9028
Trazodone HclTrazodone Hcl7923
Rosuvastatin CalciumRosuvastatin Calcium7726
Tramadol HclTramadol Hcl7715
Zolpidem TartrateZolpidem Tartrate7515
Escitalopram OxalateEscitalopram Oxalate6721
GlimepirideGlimepiride6119
OmeprazoleOmeprazole5819
Citalopram HbrCitalopram Hydrobromide5414
AllopurinolAllopurinol5215
Fluticasone PropionateFluticasone Propionate5121
TemazepamTemazepam50suppressed
Sertraline HclSertraline Hcl4913
Fluoxetine HclFluoxetine Hcl48suppressed
Metformin HclMetformin Hcl4813
Albuterol Sulfate HfaAlbuterol Sulfate4616
DiazepamDiazepam4612
LorazepamLorazepam46suppressed
EliquisApixaban40suppressed
MeloxicamMeloxicam4012
Bupropion XlBupropion Hcl3812
PrednisonePrednisone3829
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide31suppressed
Pioglitazone HclPioglitazone Hcl3112
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine28suppressed
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25suppressed
OzempicSemaglutide25suppressed
Venlafaxine Hcl ErVenlafaxine Hcl24suppressed
Acetaminophen-CodeineAcetaminophen With Codeine23suppressed
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide23suppressed
Diclofenac SodiumDiclofenac Sodium20suppressed
Potassium ChloridePotassium Chloride20suppressed
ClonazepamClonazepam19suppressed
JardianceEmpagliflozin19suppressed
Pravastatin SodiumPravastatin Sodium19suppressed
Propranolol HclPropranolol Hcl19suppressed
Warfarin SodiumWarfarin Sodium19suppressed
AzithromycinAzithromycin1816
Bupropion Hcl SrBupropion Hcl18suppressed
ClopidogrelClopidogrel Bisulfate18suppressed
Enalapril MaleateEnalapril Maleate18suppressed
FamotidineFamotidine18suppressed
Methylphenidate HclMethylphenidate Hcl18suppressed
Metoprolol TartrateMetoprolol Tartrate18suppressed
MounjaroTirzepatide18suppressed
FarxigaDapagliflozin Propanediol17suppressed
Benazepril HclBenazepril Hcl16suppressed
FurosemideFurosemide16suppressed
Olmesartan MedoxomilOlmesartan Medoxomil16suppressed
Ondansetron OdtOndansetron16suppressed
Doxycycline MonohydrateDoxycycline Monohydrate1511
JanuviaSitagliptin Phosphate15suppressed
MirtazapineMirtazapine15suppressed
FinasterideFinasteride14suppressed
Memantine HclMemantine Hcl14suppressed
Triamcinolone AcetonideTriamcinolone Acetonide14suppressed
Advair HfaFluticasone Propion/Salmeterol13suppressed
Lisdexamfetamine DimesylateLisdexamfetamine Dimesylate13suppressed
Oxycodone HclOxycodone Hcl13suppressed
SynthroidLevothyroxine Sodium13suppressed
AripiprazoleAripiprazole12suppressed
AtenololAtenolol12suppressed
PaxlovidNirmatrelvir/Ritonavir1212
ValacyclovirValacyclovir Hcl12suppressed
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide12suppressed
Diltiazem 24hr Er (Cd)Diltiazem Hcl11suppressed
RamiprilRamipril11suppressed
RivastigmineRivastigmine11suppressed
Spiriva RespimatTiotropium Bromide11suppressed
Tolterodine Tartrate ErTolterodine Tartrate11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $98.14 · 2 records Becton, Dickinson and Company Azstarys, HemoSphere
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error